Notizie | bioMérieux Italia

bioMérieux launches the BIOFIRE^® FILMARRAY^® Pneumonia Panels with FDA clearance and CE Marking

13 Novembre, 2018

bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market

09 Novembre, 2018

bioMérieux – Business review for the nine months ended

30 Settembre, 2018

bioMérieux – First-Half 2018 Results

05 Settembre, 2018

bioMérieux – Second-Quarter 2018 Business Review

18 Luglio, 2018

bioMérieux launches ENDOZYME^® II GO, an innovative test for the detection of endotoxins in pharmaceutical microbiology control

31 Maggio, 2018

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking Consensus Statement of Best Practices to Enhance Recovery after Heart Surgery

02 Maggio, 2018

bioMérieux and the University of Antwerp award scholarships to three healthcare professionals for their commitment to improve antibiotic use in order to combat antimicrobial resistance

23 Aprile, 2018

bioMérieux – First-Quarter 2018 Business Review

19 Aprile, 2018

bioMérieux submits for FDA Clearance of the BIOFIRE^® FILMARRAY^® Pneumonia Panel

19 Aprile, 2018

Pioneering diagnostics

bioMérieux Corporate | bioMérieux Industry | bioMérieux Diagnostics

bioMérieux Italia Spa | Sede Legale Via di Campigliano, 58 Loc.Ponte a Ema

50012 Bagno a Ripoli (FI) Italia | Capitale Sociale € 9.000.000 i.v. Socio Unico

n.REA FI 443558 | C.F. 07146020586 | P.IVA 01696821006